The group aims to discover and validate new biomarkers, as well as develop clinical models that are relevant in vitro and in vivo, emphasising the identification of predictive markers, with the ultimate goal of improving the diagnosis and prognosis of these types of cancer.

The group takes part in international multidisciplinary consortia and collaborative research programmes. It also works with academic groups and pharmaceutical companies on the validation of repositioning drugs or candidate drugs, while extending collaboration with other VHIO teams.

Visit the research group’s page